Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sirt1/2-IN-3 (compound PS9) serves as a dual inhibitor of SIRT1/2, exhibiting IC50 values of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respectively. This compound effectively inhibits p53 deacetylation while simultaneously elevating p53 and α-tubulin acetylation levels. Additionally, Sirt1/2-IN-3 promotes apoptosis and exhibits antiproliferative effects on human leukemia cell lines [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | Sirt1/2-IN-3 (compound PS9) serves as a dual inhibitor of SIRT1/2, exhibiting IC50 values of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respectively. This compound effectively inhibits p53 deacetylation while simultaneously elevating p53 and α-tubulin acetylation levels. Additionally, Sirt1/2-IN-3 promotes apoptosis and exhibits antiproliferative effects on human leukemia cell lines [1]. |
In vitro | Sirt1/2-IN-3 (compound hsa55) induces apoptosis in various tumor cells at 5 μM after 48 hours, with IC50 values of 6.5 μM (MV4-11), 9.2 μM (MOLM-13), 27.2 μM (THP1), and 17.4 μM (Jurkat) [1]. At 100 μM for 30 minutes, it reduces the thermal stability of SIRT1 and SIRT2 proteins at different temperatures and increases acetylated p53 and α-tubulin levels in MOLM-13 cells at 25 μM and 30 μM over 24 hours [1]. |
Molecular Weight | 363.82 |
Formula | C17H14ClNO4S |
Cas No. | 301313-42-8 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.